The number of approvals is really only 1 piece of the pie,” said Nicole A. Caffiero, PharmD, MBA, BCACP, senior clinical ...

T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access ...

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower ...

Sputum is considered a noninvasive marker of airway inflammation, and its color is an indicator of bronchiectasis disease ...

A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and ...

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most ...

Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs ...

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for ...